Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
nonalcoholic steatohepatitis (NASH)
Marketing
Madrigal maps out 'Way Forward' for MASH patients with Rezdiffra
Madrigal's Rezdiffra is the first drug FDA-approved to treat MASH. Its first ad campaign is hoping to direct patients toward that newly paved pathway.
Andrea Park
Sep 6, 2024 6:30am
With FDA nod for Iqirvo, Ipsen and Genfit will take on Intercept
Jun 11, 2024 11:07am
Madrigal builds launch infrastructure for MASH drug Rezdiffra
May 7, 2024 11:56am
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
After MASH OK, Madrigal plots $600M stock sale to support launch
Mar 19, 2024 5:17pm
FDA approves first drug for MASH in Madrigal's Rezdiffra
Mar 14, 2024 3:56pm
